Here we explore the evolution and impact of market exclusivity policies in the EU and US, highlighting their role in fostering innovation and accessibility in rare disease treatment.

Market exclusivity for orphan drugs traces back to the early 1980s in the United States, with the landmark Orphan Drug Act of 1983. This legislation emerged from a pressing need to address orphan conditions, i.e., conditions that were abandoned or orphaned by the pharmaceutical industry, deemed unprofitable due to the small number of affected patients (fewer than 200,000 Americans). The act provided a compelling incentive for drug manufacturers: seven years of market exclusivity, during which other manufacturers of the same drug for the same condition could not enter the market, regardless of the patent status. This was a turning point, igniting a wave of research and development into treatments for rare diseases that had previously been neglected.

The European Union took note of the success seen in the US and, after much deliberation and after witnessing the positive impact on rare disease patients’ lives, introduced its own legislation. In 2000, the EU established its Orphan Drug Regulation, offering a ten-year market exclusivity from similar products within the same indication, to encourage the development of drugs for conditions affecting not more than five in 10,000 citizens. This move was crucial in harmonizing efforts across member states and fostering a supportive environment for research into rare diseases.

 

What market exclusivity looks like in the US and EU

Market exclusivity for orphan drugs is a regulatory mechanism designed to incentivize pharmaceutical companies to develop treatments for rare diseases. This exclusivity grants the drug manufacturer a specific period during which no similar medicinal products can be approved for the same therapeutic indication, irrespective of patent status. This period, seven years in the United States under the Orphan Drug Act of 1983 and ten years in the European Union as per the Orphan Drug Regulation of 2000, provides a critical market advantage, allowing the company to recover the costs of research, development, and marketing without competitive products.

 

Possibilities of extending market exclusivity period by addressing the pediatric population

In both the EU and the US, pharmaceutical companies can extend the market exclusivity periods of their drugs by addressing pediatric populations in their drug development. Under the Pediatric Regulation, companies in the EU that conduct clinical trials in children as part of an agreed Pediatric Investigation Plan (PIP) can receive a six-month extension to their existing market exclusivity or patent protection. Similarly, the US Food and Drug Administration (FDA) also offers an additional six months of exclusivity to companies that test their drugs in children under the Best Pharmaceuticals for Children Act (BPCA). This extension is provided when companies conduct FDA-requested pediatric studies, regardless of the study’s outcomes. These incentives are designed to encourage the development and assessment of pharmaceuticals for pediatric use, ensuring that treatments are safely and effectively tailored to children, who may respond differently to medications than adults.

 

Patent vs. market exclusivity periods

Patents and exclusivity are critical mechanisms in the pharmaceutical industry, governed by separate statutes. Patents, issued by the United States Patent and Trademark Office, provide broad property rights during drug development. Exclusivity, granted upon FDA approval of a drug, delays competitor approvals and is contingent on meeting specific statutory criteria.

Although patents and exclusivity may overlap, they do not necessarily run concurrently and can cover different aspects of the drug. The system is designed to balance the need for innovation in drug development with the public’s need for more accessible drugs through generic competition. Patents typically last 20 years from the filing date, but various factors can affect this duration. Exclusivity, attached upon drug approval, can expire before the patent does. This leads to situations where a drug might have patent protection, exclusivity, both, or neither, depending on specific circumstances and timing.

 

Beyond market exclusivity: Other benefits of orphan drug status

Gaining orphan drug status brings several substantial benefits to pharmaceutical companies. The most direct benefit is market exclusivity, which prohibits competitors from marketing similar drugs for the same condition for a period (7 years in the US and 10 years in the EU) after the drug’s approval. Other benefits include:

 

Tax credits through the Orphan Drug Credit (US)

Initially, from 1983 until 2018, the orphan drug credit allowed companies to deduct 50% of the expenses associated with clinical testing under section 505(i) of the Federal Food, Drug, and Cosmetic Act. However, changes made to the tax code in 2017 during the Donald Trump administration reduced this credit to 25%, effective starting in 2018.

 

Grant funding for orphan drug development

The FDA allocates funds to support research, including projects on developing treatments for rare diseases. A comprehensive list can be accessed on the NIH Grants and Funding page for those interested in opportunities for rare disease product development funding from the FDA. The European Medicines Agency (EMA) does not offer research grants for sponsors of orphan medicines, but funding is available from the European Commission and other sources.

 

Reduced fees for regulatory filings

In the pharmaceutical industry, one significant incentive provided to companies developing orphan drugs is reduced fees for regulatory filings. This benefit lowers the financial barrier for companies during the approval process for drugs that treat rare diseases. By offering reduced fees associated with submitting applications for drug approval, such as New Drug Applications (NDA) or Biologics License Applications (BLA), regulatory agencies like the FDA help offset high drug development costs.

 

Assistance in the drug approval process

Regulatory agencies such as the FDA and the EMA support pharmaceutical companies in developing and approving orphan drugs. These agencies offer guidance on clinical trial design tailored for rare conditions, including advice on endpoints and study populations. They also provide advice meetings to address various development challenges. To expedite approval for orphan drugs where there is an unmet medical need, the FDA offers pathways such as Fast Track and Breakthrough Therapy Designation, and EMA offers Priority Review.

Furthermore, these agencies significantly reduce or waive application fees and show regulatory flexibility by accepting innovative statistical methods or less traditional evidence to evaluate drug efficacy. This comprehensive support helps mitigate the complexities of bringing treatments for rare diseases to market, facilitating quicker access to critical medications.

 

Final takeaways

The evolution and impact of market exclusivity policies in the EU and US have significantly shaped the landscape of rare disease treatment, fostering innovation and accessibility. Since the 1983 and 2000 landmark orphan drug designation policies came into effect, market exclusivity has served as a pivotal incentive for pharmaceutical companies to invest in the development of treatments for rare conditions. By granting periods of exclusivity, including exclusivity extensions for pediatric studies, these policies allow companies to recoup their investments in research, development, and marketing, ultimately benefiting patients by expanding the availability of life-changing therapies. As we look toward the future, continued collaboration will be essential in further advancing research and development efforts, improving outcomes for patients with rare diseases worldwide.

 

Interested in learning more?

Download our ebook, “Rare Disease Clinical Trials: Design Strategies and Regulatory Considerations”:

Orphan drug designation is a regulatory status granted to pharmaceuticals developed for the treatment of rare diseases. It provides incentives to encourage the research, development, and approval of therapies targeting small patient populations.

 

At the age of 21, Stephen Hawking, a brilliant physicist, was diagnosed with ALS (Amyotrophic Lateral Sclerosis). ALS is a rare neurodegenerative disease, affecting 4–6 out of 100,000 people. Despite the initial prognosis of just two years, Hawking’s life with ALS spanned five decades. His life story underscores the devastating impact of rare diseases on individuals and their families and the profound importance of advancing medical research and treatment options for these conditions. It highlights the dire need for orphan drug development — an endeavor that the introduction of orphan drug legislation has significantly bolstered.

Though individually uncommon, rare diseases collectively affect millions of people worldwide and present a unique set of challenges for both patients and the pharmaceutical industry. Historically, the development of treatments for these conditions has been limited, primarily due to the low-profit potential associated with small patient populations.

However, the past few decades have witnessed a significant paradigm shift, with the pharmaceutical landscape evolving to more inclusively address the needs of those suffering from rare diseases. The inception of orphan drug regulations in both the United States and the European Union has been pivotal in incentivizing the development of these crucial treatments. Rooted in the acknowledgment that traditional pharmaceutical business models inadequately cater to the needs of rare disease patients, legislation such as the Orphan Drug Act of 1983 in the U.S. and the Orphan Regulation of 2000 in the EU was introduced.

These regulations offer pharmaceutical companies a range of incentives, including tax credits, grants, and a period of market exclusivity, thereby encouraging the investment in and development of new therapies for rare diseases. To truly appreciate the impact of these regulations, one needs to consider the perspectives of patients such as Stephen Hawking and his family. It is crucial to remember the human element at the core of this discourse.

 

Understanding rare diseases

Defining rare diseases: Prevalence and impact

Rare diseases, often referred to as orphan diseases, are those that affect a small fraction of the population. Although the threshold for what constitutes a “rare” condition varies by region. In the United States, a disease is considered rare if it affects fewer than 200,000 people at any given time (that is, about 6 per 10,000 people). The EMA considers a disease an orphan if it affects fewer than 5 in 10,000 people.1

Despite their rarity, these diseases collectively present a significant health concern, impacting millions worldwide. There are estimated to be over 7,000 rare diseases affecting an estimated 300 million people globally. The diversity of these conditions, ranging from genetic disorders to rare cancers, poses unique challenges in diagnosis, research, and treatment.

The impact of rare diseases extends beyond the patients; it affects families, caregivers, and the healthcare system. Patients often face a long and arduous journey toward receiving a correct diagnosis, sometimes called the “diagnostic odyssey,”2 which can span several years and involve numerous misdiagnoses. This delay in diagnosis exacerbates patient suffering, hampers effective treatment, and significantly affects the quality of life of patients and their families.

 

Challenges in developing treatments for orphan drugs

Developing treatments for rare diseases is fraught with challenges, chief among them being the economic viability of investing in therapies for small patient populations. The limited market potential for such treatments discourages pharmaceutical companies from pursuing research and development in this area, leading to a significant unmet medical need within these communities.

• Scientific and technical challenges: Rare diseases often have complex pathologies, with many still poorly understood. The lack of basic scientific knowledge about the underlying mechanisms of many rare diseases makes drug discovery and development particularly challenging. Moreover, the small number of patients makes conducting traditional large-scale clinical trials difficult, complicating the assessment of treatment efficacy and safety.
• Regulatory hurdles: Although regulatory agencies like the FDA and EMA have put in place frameworks to facilitate orphan drug development, navigating these regulations remains a complex process. The unique aspects of rare disease treatment development, such as the need for specialized trial designs and the acceptance of alternative endpoints, require a nuanced understanding of regulatory expectations.
• Market and financial challenges: The high cost of drug development, coupled with the small patient populations for rare diseases, poses significant financial risks for pharmaceutical companies. Although orphan drug legislation offers incentives such as tax breaks and market exclusivity, the overall financial model for orphan drugs is still challenging. The high cost of these drugs upon reaching the market also raises issues of accessibility and affordability for patients.
• Collaboration and data sharing: The rarity of these conditions necessitates global collaboration and data sharing among researchers, healthcare professionals, and patient advocacy groups. Building consortia and networks to share data, resources, and expertise is crucial but often hampered by logistical, regulatory, and proprietary barriers.

 

Benefits of orphan drug designation

The orphan drug designation provides a suite of benefits to encourage pharmaceutical companies to invest in developing treatments for rare diseases. These incentives make the pursuit of orphan drugs more appealing financially and facilitate the drug development and approval process. Here’s a closer look at the key benefits:

 

Financial Incentives for pharmaceutical companies

• Tax credits: Companies developing orphan drugs can receive significant tax credits for the costs incurred in conducting clinical trials. This financial incentive helps reduce the overall expense of drug development, making projects that might otherwise be financially unviable more attractive.
• Grant funding: In some jurisdictions, companies may apply for grant funding to support the research and development of orphan drugs. These grants can cover various activities, from preclinical studies to clinical trial phases.
• Fee waivers: Regulatory agencies often waive specific fees associated with the drug approval process for orphan drugs. This includes application fees and product registration fees, which can be substantial.

 

Regulatory support and expedited assessments

• Advice meetings: Orphan drug designation often comes with the benefit of close interaction with the regulatory agencies for advice during the development. This guidance help optimize study designs and ensure that the development program meets the regulatory requirements for approval.
• Expedited regulatory paths: Drugs with orphan designation often constitute an unmet medical need and may be eligible for Fast-Track and Breakthrough Therapy Designation in the US or Priority medicine (PRIME) in EU leading to expedited assessment by the regulatory bodies. This can significantly shorten the time to market, providing patients with quicker access to new treatments.
• Approval process: Orphan drugs are often eligible for shorter review timeline by the agency, so called Priority Review in the US and Accelerated assessment in EU. In addition to this, orphan drugs are often approved based on promising early limited clinical data. This allows the drug to be marketed while further evidence is gathered to confirm its benefit so called Accelerated Approval in US and Conditional Approval in EU.

 

Market exclusivity: What it means for orphan drug developers

• Exclusivity period: Upon approval, orphan drugs are granted a period of market exclusivity. This period varies by jurisdiction but is typically seven years in the United States3 and ten years in the European Union.4 During this time, competitors cannot market similar drugs for the same indication, providing a significant competitive advantage.
• Protection from competition: The exclusivity period provides a valuable window during which the drug developer is protected from competition, allowing them to recoup the investment in the drug’s development and potentially generate profit. This is particularly important for drugs targeting small patient populations, where the market size is inherently limited.
• Incentive for further development: The prospect of market exclusivity also incentivizes companies to invest in the development of treatments for conditions that might not otherwise attract commercial interest. It encourages innovation and investment in new therapies for rare diseases, ultimately benefiting patients with limited treatment options.

 

The process of obtaining orphan drug designation

To qualify for orphan drug designation, a drug must meet specific criteria largely consistent across regulatory agencies, though variations exist from one jurisdiction to another. Firstly, the drug in question must target a rare condition, defined based on the population it affects (see earlier section on Understanding Rare Diseases). Beyond the condition’s rarity, the application for orphan drug designation must convincingly address an unmet medical need, either because no existing treatments are available or because the new drug promises to be safer or more effective than current options.

Additionally, the application must present a scientific rationale for the drug’s use, supported by evidence or a well-founded hypothesis that the drug will effectively treat, prevent, or diagnose the specified rare disease. This comprehensive approach ensures that only drugs that genuinely have the potential to impact rare diseases significantly are granted orphan drug designation.

 

Step-by-step guide to the application process

• Pre-application research and development: Before applying for orphan drug designation, companies conduct preliminary research to establish the drug’s safety and anticipated efficacy for the target condition. Preclinical data in relevant animal models are sufficient, while clinical data is not a must.
• Preparation of application: The next step involves preparing a detailed application that includes the drug’s description, the rationale for its use in rare conditions, prevalence data, and existing evidence regarding its efficacy and safety.
• Submission to regulatory agency: Once the application is complete, it is submitted to the relevant regulatory agency, such as the United States’ FDA or the European Union’s EMA.
• Review process: The regulatory agency reviews the application to ensure it meets all eligibility criteria. This review process may involve questions or requests for additional information from the applicant.
• Designation granted: If the application is successful, the regulatory agency grants orphan drug designation, allowing the company to access the associated benefits.

Pro-tip: Leverage scientific advice in orphan drug development

In addition to orphan drug designation, pharmaceutical companies developing orphan drugs should seek advice from the regulatory agencies to strengthen their applications. This collaborative process involves obtaining guidance on the development and regulatory aspects of the drug, ensuring that the proposed studies are adequately designed to meet the regulatory standards for approval. Advice meetings can cover a wide range of topics, from the design of clinical trials, including endpoints and statistical considerations, to the quality of nonclinical studies and manufacturing processes.

Engaging with regulatory agencies for advice early in the drug development process can significantly enhance the likelihood of success, as it allows companies to align their development strategies with regulatory expectations. This proactive approach not only streamlines the development process but also reduces the risk of costly setbacks, thereby facilitating the timely introduction of new treatments for rare diseases into the market.

 

 

Challenges and controversies in orphan drug development

While the development and distribution of orphan drugs offer significant benefits to patients with rare diseases, they are not without challenges and controversies.

 

Pricing and accessibility of orphan drugs

Due to high research and development costs and small patient populations, orphan drugs are notably expensive. This limits access for patients without substantial healthcare support and pressures healthcare budgets. This has sparked debate on balancing affordability and incentives for pharmaceutical companies to develop treatments for rare diseases.

 

Ethical considerations in orphan drug development

Developing treatments for rare diseases introduces ethical dilemmas, especially in resource allocation and drug pricing. High costs can limit access to crucial treatments, raising questions about society’s investment priorities.5 Additionally, the push for quick approvals might risk patient safety, further complicating ethical considerations.

 

Balancing profit and patient access

The profitability motive of pharmaceutical companies, driven by incentives like tax breaks and exclusivity, sometimes conflicts with the need for affordable patient access to treatments. Criticism arises when companies leverage these benefits for broader profit, challenging the balance between rewarding innovation and ensuring treatment accessibility.6

 

 

 

Orphan drug designation for rare pediatric diseases

The FDA’s strategy to increase the availability of drugs in children include the Pediatric Research Equity Act (PREA)7 and the Best Pharmaceuticals for Children Act (BPCA),8 mandating pediatric study plans and offering additional market exclusivity for conducting pediatric studies, respectively. Similarly, the EMA’s Pediatric Regulation mandates the inclusion of a Pediatric Investigation Plan (PIP) in new drug applications.

Rare pediatric diseases present a particular challenge in drug development due to small patient populations and limited commercial appeal, prompting regulatory frameworks aimed at incentivizing treatment advancements. The FDA has introduced the Rare Pediatric Disease Priority Review Voucher Program, providing a unique incentive to expedite drug review processes. Despite these efforts, challenges such as the need for innovative trial designs and regulatory flexibility remain. Ongoing collaboration between regulatory agencies, pharmaceutical companies, and patient groups is essential to overcome these hurdles and improve access to treatments for children with rare diseases.

 

Final takeaways: Navigating the future of orphan drug designation

The journey toward advancing treatments for rare diseases through orphan drug designation has been transformative, offering new hope to patients facing conditions once deemed untreatable. This progress is underpinned by critical regulatory frameworks like the Orphan Drug Act in the U.S. and the Orphan Regulation in the EU. These regulations have been instrumental in encouraging pharmaceutical research and development by offering significant incentives like tax credits, grant funding, and market exclusivity. However, the journey has its challenges. The high cost of orphan drugs and their accessibility remain contentious issues, raising ethical questions about pricing strategies and the balance between profit and patient access.

A crucial aspect of navigating these challenges is leveraging scientific advice from regulatory bodies, which can significantly enhance the likelihood of success for orphan drugs. This collaborative process allows companies to align their development strategies with regulatory expectations, optimizing study designs and ensuring the development program meets the necessary approval criteria.

Furthermore, the focus on pediatric rare diseases adds another layer of complexity and urgency to the development process. Regulatory incentives designed to encourage research into pediatric conditions, such as the FDA’s Rare Pediatric Disease Priority Review Voucher Program, highlight the critical need for treatments that cater to the youngest and often most vulnerable patients.

 

Interested in learning more?

Download our ebook, “Rare Disease Clinical Trials: Design Strategies and Regulatory Considerations”: